A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats.

Qi, Min-You

A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. [electronic resource] - Journal of cardiovascular pharmacology Jun 2006 - 729-35 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0160-2446

10.1097/01.fjc.0000211765.52012.aa doi


Animals
Aspartic Acid Endopeptidases--biosynthesis
Blood Pressure
Blotting, Western
Calcium-Binding Proteins--biosynthesis
Cardiomyopathies--drug therapy
Diabetes Complications--drug therapy
Diabetes Mellitus, Experimental
Down-Regulation
Endothelin Receptor Antagonists
Endothelin-Converting Enzymes
Heart Rate
Male
Metalloendopeptidases--biosynthesis
Myocardium--metabolism
Nitric Oxide Synthase Type II--biosynthesis
Organ Size
Oxidative Stress
Pyrazoles--therapeutic use
RNA, Messenger--analysis
Rats
Rats, Sprague-Dawley
Reverse Transcriptase Polymerase Chain Reaction
Ryanodine Receptor Calcium Release Channel--biosynthesis
Sarcoplasmic Reticulum Calcium-Transporting ATPases--biosynthesis
Streptozocin
Tacrolimus Binding Protein 1A--biosynthesis
Up-Regulation
Vasoconstrictor Agents--therapeutic use